Sugi Predict

Sugi Predict / Compounds / SCHEMBL2383906

SCHEMBL2383906

SCHEMBL2383906

O=C1CCC(N2C(=O)c3cccc(NCc4ccco4)c3C2=O)C(=O)N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 16/20 1.00
▸ CRBN Q96SW2 16/20 1.00
▸ HDAC1 Q13547 2/20 0.59
▸ HDAC2 Q92769 2/20 0.59
▸ IKZF3 Q9UKT9 2/20 0.57
▸ TNF P01375 1/20 0.57
▸ IL1B P01584 1/20 0.57
▸ TBXA2R P21731 1/20 0.57
▸ IKZF1 Q13422 1/20 0.57
▸ STAT3 P40763 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ CHRM2 P08172 1/20 0.54
▸ OPRM1 P35372 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29453443 1.00 DDB1 (1.00) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL12250740 1.00 DDB1 (1.00) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL12250755 1.00 DDB1 (1.00) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL13464308 0.90 DDB1 (0.82) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL26318118 0.86 DDB1 (0.94) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL2382539 0.85 DDB1 (0.75) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL29922115 0.85 DDB1 (1.00) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL12250737 0.85 DDB1 (1.00) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL12250752 0.85 DDB1 (1.00) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL476935 0.85 DDB1 (1.00) DDB1CRBNHDAC1HDAC2IKZF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168958-A1 Isoindole-Imide Compounds, Compositions And Uses Thereof CELGENE CORPORATION (US) 2010-03-31 — — EP claimed
EP-1363900-A1 ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS CELGENE CORPORATION (US) 2003-11-26 — — EP claimed
US-20030096841-A1 Isoindole-imide compounds, compositions, and uses thereof CELGENE CORPORATION 2003-05-22 — — US claimed
US-20030045552-A1 Isoindole-imide compounds, compositions, and uses thereof CELGENE CORPORATION 2003-03-06 — — US claimed
WO-2002059106-A1 ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF CELGENE CORPORATION (US) 2002-08-01 — — WO claimed
US-12023385-B2 Tunable endogenous protein degradation with heterobifunctional compounds DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-07-02 — — US disclosed
EP-3256470-B1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA FARBER CANCER INST INC (US) 2023-07-26 — — EP disclosed
EP-4119552-A1 REGULATING CHIMERIC ANTIGEN RECEPTORS Dana-Farber Cancer Institute, Inc. (US) 2023-01-18 — — EP disclosed
CN-108350062-B Targeted protein degradation to attenuate adverse inflammatory responses associated with adoptive T cell therapy 达纳-法伯癌症研究所股份有限公司 2022-10-14 — — CN disclosed
EP-3331905-B1 TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES DANA FARBER CANCER INST INC (US) 2022-10-05 — — EP disclosed
US-20220135967-A1 TUNABLE ENDOGENOUS PROTEIN DEGRADATION DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-05-05 — — US disclosed
US-11311609-B2 Regulating chimeric antigen receptors DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-26 — — US disclosed
US-7576104-B2 Isoindole-imide compounds, compositions, and uses thereof CELGENE CORPORATION (US) 2009-08-18 — — US disclosed
US-7576104-B2 Isoindole-imide compounds, compositions, and uses thereof CELGENE CORPORATION (US) 2009-08-18 — — US disclosed
EP-1767533-A1 N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor CELGENE CORPORATION (US) 2007-03-28 — — EP disclosed
EP-1767533-A1 N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor CELGENE CORPORATION (US) 2007-03-28 — — EP disclosed
US-7091353-B2 Isoindole-imide compounds, compositions, and uses thereof CELGENE CORPORATION (US) 2006-08-15 — — US disclosed
US-20060025597-A1 Isoindole-imide compounds, compositions, and uses thereof CELGENE CORPORATION 2006-02-02 — — US disclosed
EP-1363900-A1 ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS CELGENE CORPORATION (US) 2003-11-26 — — EP disclosed
WO-2002059106-A1 ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF CELGENE CORPORATION (US) 2002-08-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045552-A1 Isoindole-imide compounds, compositions, and uses thereof TNF, IKZF3, IKZF1 DDB1 3650/4885CRBN 1511/4885HDAC1 446/4885
US-20060025597-A1 Isoindole-imide compounds, compositions, and uses thereof TNF, IKZF3, TNFRSF1A DDB1 3627/4885CRBN 1695/4885HDAC1 487/4885
US-12023385-B2 Tunable endogenous protein degradation with heterobifunctional compounds DBN1, MYCBP, PSMG3 DDB1 10/4885CRBN 158/4885HDAC1 4320/4885
US-20030096841-A1 Isoindole-imide compounds, compositions, and uses thereof TNF, IKZF3, IKZF1 DDB1 3650/4885CRBN 1511/4885HDAC1 446/4885
US-11311609-B2 Regulating chimeric antigen receptors NFATC1, TNFRSF9, IL2RA DDB1 979/4885CRBN 154/4885HDAC1 2500/4885
US-20220135967-A1 TUNABLE ENDOGENOUS PROTEIN DEGRADATION PSMG3, MYCBP, DBN1 DDB1 26/4885CRBN 138/4885HDAC1 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.